Finanzas de EyePoint Inc (EYPT)EYPTEyePoint Inc

EyePoint Inc (EYPT) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is YUTIQ, accounting for 91.5% of total sales, equivalent to $9.02M. Another important revenue stream is DEXYCU. Understanding this composition is critical for investors evaluating how EYPT navigates market cycles within the Pharmaceuticals industry.

Evaluating the bottom line, EyePoint Inc maintains a gross margin of 100.00%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -19207.10%, while the net margin is -18633.14%. These profitability ratios, combined with a Return on Equity (ROE) of -148.70%, provide a clear picture of how effectively EYPT converts its operational activities into shareholder value.

In the context of the broader market, EYPT competes directly with industry leaders such as ABEO and OCGN. With a market capitalization of $36.91M, it holds a significant position in the sector. When comparing efficiency, EYPT's gross margin of 100.00% stands against ABEO's 63.30% and OCGN's 100.00%. Such benchmarking helps identify whether EyePoint Inc is trading at a premium or discount relative to its financial performance.

The company has reported substantial losses, with net income to common reaching -$94.47 million in Q2 2026 and a gross margin fluctuating significantly, peaking at 96.71% in Q1 2025 but dropping to 24.14% in Q1 2026.